The Vexation Word firmLa Merie S.L. reported twenty-four hours that Sanofi-Aventis' first-in-class CB1 drug Acomplia (rimonabant) has at least five competitors in clinical stages up to period of time III and many more in earlier phases of R&D. While Acomplia received EU commendation in June 2006, the FDA requested more time to proceedings the file. Acomplia is indicated for the direction of patients with obesity or overweight plus cardiometabolic risk factors and achieved EU sales of 31 mln in its point in time months in selected markets.
However, some countries such as Germany consider Acomplia as a non-reimbursable life-style drug. Sanofi-Aventis is craft a huge clinical system to strikingness Acomplia in additional populations such as in type 2 diabetes (1st line), insulinized patients, dyslipidemia or atherosclerosis. Another athletic field of electrical phenomenon use of CB1 antagonists lies in neuroscience, such as dependence and cognitive disorders. These results and more were found in a operation conducted by La Merie Commercialism Power. The competitor reasoning of CB1 antagonists can be acquired at La Merie's News Place and Online Accumulation.